News >

Armamentarium Continues to Evolve Across Metastatic Prostate Cancer

Caroline Seymour
Published: Monday, Aug 26, 2019

Manish Kohli, MD

Manish Kohli, MD

The therapeutic arsenal for men with metastatic hormone-sensitive prostate cancer (mHSPC) continues to expand with targeted agents, such as enzalutamide (Xtandi) and apalutamide (Erleada), explained Manish Kohli, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 3rd Annual International Congress on Oncology & Pathology™Aug 30, 20201.5
Community Practice Connections™: ASCO Direct™ Highlights – 2019 Official Annual Meeting ReviewAug 30, 20201.5
Publication Bottom Border
Border Publication
x